54 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
following the date of termination; (B) any unpaid Annual Bonus (as defined in Executive’s Employment Agreement) relating to the year prior to the year … in which the Annual Bonus, if any, was earned; (C) at the discretion of the Board of Directors of the Company (the “Board”) a prorated amount of any Annual
8-K
ADAP
Adaptimmune Therapeutics plc
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
(or an authorized committee thereof), the executive officer may be paid a lump sum cash amount equal to his or her annual performance bonus for the year … , the executive officer will be paid a lump sum cash amount equal to a 12 month bonus for the year of termination calculated based on the target bonus
8-K
ADAP
Adaptimmune Therapeutics plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
cash amount equal to his or her annual performance bonus for the year of termination, prorated based on the number of calendar days the executive … bonus for the year of termination calculated based on the target bonus for the year of termination (formerly, the actual bonus under the 2017 Executive
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
; (B) any unpaid Annual Bonus (as defined in Executive’s Employment Agreement) relating to the year prior to the year in which the date of termination … of employment occurs, paid in a single lump sum no later than March 15 of the year following the calendar year in which the Annual Bonus, if any
8-K
d7ug3 bnpi
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
j76m63 u4
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
g2whdhzmkas07mci uua
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
m519pdqsb0 dffsx3blj
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
fhrjxr 2gsshanla1jo
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
g03bt7zn v09xqu
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
3rfrs bnbuobeh9vic
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
zhel 7gqs
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am